Keyphrases
Franseen Needle
80%
Hepatitis C Virus
76%
Endoscopic Ultrasound-guided Fine-needle Aspiration (EUS-FNA)
66%
Unresectable Hepatocellular Carcinoma
60%
Overall Survival
60%
Thrombocytopenia
60%
Post-progression Survival
47%
Hepatitis C Virus Infection
42%
Direct-acting Antivirals
40%
Solid Pancreatic Lesions
40%
Immune-related Adverse Events
40%
Velpatasvir
40%
Sofosbuvir
40%
Reaction-based
40%
Endoscopic Ultrasound
40%
Decompensated Cirrhosis
40%
19-gauge
40%
Nested PCR (nPCR)
40%
Histological Samples
40%
Diagnostic Results
40%
Human Immunodeficiency Virus Infection
40%
Intrahepatic Bile Duct
40%
Successful Treatment
40%
Bile Duct Injury
40%
Endoscopic Ultrasound Guided Biopsy
40%
Biopsy Needle
40%
Ultrasound Examination
40%
Immune Checkpoint Inhibitor Treatment
40%
Fine-needle Aspiration Biopsy
40%
Progression-free Survival
38%
Pathological Diagnosis
33%
22-gauge
30%
Hepatocellular Carcinoma
28%
Lenvatinib
28%
Hepatitis C Virus Genotypes
26%
Nasal
26%
Genetic Test
26%
Japan
26%
Transcatheter Arterial Embolization
25%
Atezolizumab Plus Bevacizumab
22%
Second-line Treatment
22%
Hepatitis C Virus Eradication
20%
Leukopenia
20%
Combination Immunotherapy
20%
Autopsy Cases
20%
Sarcomatoid Hepatocellular Carcinoma
20%
Histopathological Examination
20%
Hepatic Angiosarcoma
20%
Malignant Lesions
20%
Retrospective Cohort Study
20%
Medicine and Dentistry
Endoscopic Ultrasound
80%
Fine-Needle Aspiration
80%
Endoscopic Ultrasound Guided Fine Needle Biopsy
71%
Hepatocellular Carcinoma
60%
Thrombocytopenia
60%
Biopsy Technique
46%
Overall Survival
40%
Immune-Related Adverse Events
40%
Immune Checkpoint Inhibitor
40%
Velpatasvir
40%
Sofosbuvir
40%
Decompensated Liver Cirrhosis
40%
Bile Duct Injury
40%
Intrahepatic Bile Duct
40%
Diagnosis
40%
N [bis(1 Aziridinyl)phosphinyl] 4 Iodobenzamide
40%
Neoplasm
39%
Hepatitis C Virus
33%
Hepatitis C
29%
Lenvatinib
28%
Pancreas Cancer
27%
Ascites
26%
Arterial Embolization
25%
Systematic Review
22%
Leukopenia
20%
Sarcomatoid
20%
Patient Characteristics
20%
Antivirus Agent
20%
Immunotherapy
20%
Tail
20%
Blood Clot
20%
Retrospective Cohort Study
20%
Angiosarcoma
20%
Viral Clearance
20%
Linitis Plastica
20%
Progression Free Survival
18%
Diagnostic Accuracy
16%
Steroid Treatment
16%
Omeprazole
13%
Intractable Epilepsy
13%
Antiviral Therapy
13%
Platelet
13%
Nutrition
13%
Spastic Diplegia
13%
Malignant Neoplasm
8%
Metastatic Carcinoma
8%
Multivariate Analysis
8%
CD8 Antigen
8%
Keratin 7
8%
Immunosuppressive Treatment
8%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Overall Survival
60%
Thrombocytopenia
60%
Antivirus Agent
53%
Hepatitis C Virus
53%
Sofosbuvir
40%
Velpatasvir
40%
Decompensated Liver Cirrhosis
40%
Progression Free Survival
38%
Hepatitis C
29%
Lenvatinib
28%
Ascites
26%
Atezolizumab
22%
Bevacizumab
22%
Leukopenia
20%
Cohort Study
20%
Viral Clearance
20%
Immunotherapy
20%
Molecular Target
20%
Wilson's Disease
20%
Tenofovir Alafenamide
20%
Intractable Epilepsy
13%
Tablet
13%
Cerebral Palsy
13%
Neoplasm
13%
Recurrent Disease
8%
Sorafenib
7%
Antiviral Therapy
5%
Liver Cirrhosis
5%
